ClinicalTrials.gg
TerminatedNCT06761586VIJAY-1Updated Apr 17, 2026

A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)

A Phase 1 interventional study of AUR104 in Select Relapsed/Refractory Lymphoid Malignancies, sponsored by Aurigene Discovery Technologies Limited. Terminated at 5 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Aurigene Discovery Technologies Limited (part of Dr. Reddy's Laboratories Limited) · Phase 1, Interventional, and Treatment

Why this study was terminated
Patient recruitment problems

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies. The main objective of the study is to evaluate the safety and tolerability of the study drug AUR104.In this study, safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AUR104 will be evaluated in dose escalation manner.

Read the detailed description

This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies. The dose escalation will be conducted in a rule-based manner in patients who do not have any available curative treatment options and have exhausted all effective therapies available locally. At a minimum, the patients must have relapsed or refractory disease to at least 2 prior lines of systemic therapies for NHL or CLL, or Hodgkin's disease. The main objective of the study is to evaluate the safety and tolerability of the study drug AUR104. In this study, safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AUR104 will be evaluated in dose escalation manner.

02

Conditions studied

  • Select Relapsed/Refractory Lymphoid Malignancies

Keywords

  • Relapsed/Refractory Lymphoid Malignancies
  • Non-Hodgkin Lymphoma (NHL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Hodgkin Lymphoma (HL)
03

In context

Lead sponsor

Aurigene Discovery Technologies Limited is the lead sponsor of 12 studies on the registry; 4 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 years of age.
  2. (ECOG) Performance status of 0 or 1.
  3. Acceptable bone marrow and organ function at screening as described below:

    • ≥ 1000/μL (without WBC growth factor support)
    • count: For patients with CLL ≥ 50,000/μL, For patients with lymphomas ≥ 75,000/μL without bone marrow involvement and ≥ 50,000/μL with bone marrow involvement. These thresholds should be qualified without current transfusion support.
    • ≥ 9 g/dL (Transfusion is allowed to achieve this Hb).
    • Total ≤ 1.5 x (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin ≤ 2.5 x ULN).
    • (SGOT) ≤ 3 x ULN (≤ 5 × ULN if known liver ).
    • ALT (SGPT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases).
    • (CrCl) ≥ 60 mL/min (either measured or estimated by the Cockcroft-Gault formula). Cockcroft-Gault formula for estimated creatinine clearance (eCrCl):(140 - Age) × Weight (kg) × (0.85 if Female)/(72 × serum creatinine in mg/dL).
  4. Ability to swallow and retain oral medications.
  5. Histopathological diagnosis of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) or Hodgkin disease.

Note:

5a. The lymphoma should be either in Stage III or IV according to Lugano classification at screening.

5b. The lymphomas included in this study must fall within one of the following 2017 World Health Organization categories except lymphoma mentioned in Exclusion criterion #5:

  • Mature B-cell neoplasms (excluding plasma cell neoplasms, heavy chain disease, and primary central nervous system [CNS] lymphoma).
  • Mature T- and NK-cell neoplasms.
  • Hodgkin lymphomas. 5c. The CLL should be Binet Stage C/Rai stage III or IV, as per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines.

    6) In the case of patients who have lymphoid for which high-dose chemotherapy and stem cell transplantation (HD-ASCT) is considered standard curative therapy, eligibility for this study requires that the disease has after HD-ASCT, or the subject is not eligible for HD-ASCT, or the subject has refused HD-ASCT.

    7) In the case of patients who have lymphoid malignancies for which CAR-T therapy is indicated, eligibility for this study requires that the disease has relapsed after CAR-T, or the patient is not eligible for CAR-T, or the patient has refused CAR-T, or the CAR-T is not available locally.

    8) Evidence of as per Lugano Criteria for Lymphoma or evidence of measurable disease as per iwCLL Criteria for CLL.

Note: Patients with Small Lymphocytic Lymphoma (SLL) alone or in combination with CLL are allowed.

9) Standard curative measures do not exist, and the patient must have exhausted all effective therapies available locally. At a minimum, the patients must have relapsed or refractory disease to at least 2 for NHL or CLL, or Hodgkin's disease.

Note: Any cancer patient with access to any effective therapy locally must not be enrolled.

Exclusion criteria

Exclusion Criteria:

  1. Systemic anti-cancer therapy, such as chemotherapy, biological therapy, or immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from Cycle 1 Day 1 of the study.

    Note: Concomitant use of low-dose prednisone (up to 10 mg/day) is allowed.

  2. Presence of acute or chronic toxicity resulting from prior anti-cancer treatment, except for alopecia or nail changes that have not resolved to Grade ≤ 1, as determined by v 5.0.
  3. Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed and no restrictions during the screening period or during the trial).
  4. Use of any agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  5. Patients with Burkitt's lymphoma, Burkitt-like lymphoma, post-transplant lymphoproliferative disease, primary mediastinal large-B cell lymphoma, cutaneous lymphomas, mycosis fungoides (MF), or Sezary syndrome (SS).
  6. Known symptomatic or untreated or recently treated (≤ 6 months of screening) central nervous system (CNS) lymphoma. Patients with previously treated (more than 6 months of screening) CNS lymphoma and are now stable and asymptomatic, from a CNS perspective, are allowed.
  7. Patients with lymphoma requiring immediate cytoreductive therapy.
  8. Patients with low-grade or indolent lymphoma not meeting conventional criteria for treatment.
  9. Elevated Serum cardiac Troponin I or troponin T more than at screening.
  10. Serum magnesium and calcium levels more than 1.2 x ULN or less than 0.8 x LLN.
  11. Serum Potassium more than 1.0 x ULN or less than 1.0 x LLN. Note: Patients experiencing hypokalemia are permitted to undergo treatment to attain normal potassium levels during the screening period.
  12. Mean Heart Rate less than 60 at screening or Cycle 1 Day 1 (to be recorded at least 3 times at least 5 minutes apart) in .
  13. (LVEF) less than 50% as determined by an echocardiogram (ECHO) or Multigated Acquisition (MUGA) scan.
  14. (Fridericia) interval more than 450 ms for patients on ECG at screening and/or at Cycle 1 Day 1.
  15. Uncontrolled arterial hypertension defined as supine SBP of ≥ 140 mm Hg AND/OR supine DBP ≥ 90 mmHg on stable doses of three or lesser different classes of antihypertensive drugs.

    Notes:

    • Patients taking 4 or more classes of antihypertensives are excluded. Diuretics (such as furosemide or spironolactone) are considered as one class of anti-hypertensives.
    • The blood pressure has to be recorded 3 times at least 10 minutes apart during Screening and Cycle 1 Day 1 (before dosing) in the supine position. Among these recordings, a single instance of SBP ≥140 mm Hg or DBP ≥ 90 mmHg will exclude the patient. Note: A patient excluded on these criteria can be re-screened after optimal BP management.
  16. Current or past history of heart failure ( Class 2 or higher)
  17. Having a history of moderate to severe cardiovascular disease including unstable angina, myocardial infarction, cerebrovascular accident, or (TIA), within 1 year prior to Cycle 1 Day 1.
  18. Ongoing cardiac arrhythmias or conduction blocks.
  19. History of any ventricular arrhythmia including supraventricular or ventricular premature contractions.
  20. Patients on drugs which are sensitive substrates of and cannot be discontinued at least one week prior to Cycle 1 Day 1.
  21. Use of strong CYP3A4 inhibitors or inducers within 2 weeks prior to Cycle 1 Day 1.
  22. Concomitant use of any drug which is known to prolong QTc interval or use of such drugs within one week prior to Cycle 1 Day 1.
  23. Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia)
  24. Active infection requiring systemic therapy. Note: Prophylactic use of antibiotics is allowed. Any infection detected during the screening period, which is resolved adequately according to the investigator before Cycle 1 Day 1, is allowed.
  25. Known to be (HIV) positive or have an acquired immunodeficiency syndrome-related illness.
  26. Known active or chronic (HBsAg +ve) or infection (HCV antibody +ve).
  27. Patient expected to require any other form of antineoplastic therapy or targeted therapy while in the study.
  28. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g., renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or psychiatric illness/social situations or laboratory / ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study
  29. Current swab-positive or suspected (under investigation) Covid-19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of the person(s) with confirmed Covid-19 infection, at screening or Cycle 1 Day 1.
  30. History of another primary within 5 years prior to starting the study drug, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ or cured early-stage (Stage 1 or 2) prostate cancer.
  31. Positive pregnancy test for women of (WOCBP) at the screening or enrollment visit
  32. Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable methods (hormonal contraceptive, IUD, or any double combination of male or female condom, spermicidal gel, diaphragm, sponge, cervical cap).
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    AUR104 5mg & 20 mg Tablets

    Currently planned dose levels are 20 mg QD, 10 mg BID and 15 mg BID.

    Drug: AUR104

Interventions

  • DrugAUR104

    Once or twice a day

06

What researchers measure

Primary outcomes

  1. First cycle DLT

    Assess dose limiting toxicities of AUR104

    Time frame: 28 days (Cycle 1)

  2. Frequency of Adverse Events

    Adverse Events will be assessed by NCI CTCAE v 5.0

    Time frame: Throughout the study, an average of 1 year

  3. Frequency of Serious Adverse Events

    Serious Adverse Events will be assessed by NCI CTCAE v 5.0

    Time frame: Throughout the study, an average of 1 year

  4. Pharmacokinetics: Area under the curve (AUC)

    Area under the curve of AUR104

    Time frame: Cycle 1 Day 1 and Day 9 (Cohorts 1, 2, and 3); Cycle 1 Day 5 (only Cohort 3) (Each cycle is 28 days)

  5. Pharmacokinetics: Maximum plasma concentration (Cmax)

    Maximum plasma concentration of AUR104

    Time frame: Cycle 1 Day 1 and Day 9 (Cohorts 1, 2, and 3); Cycle 1 Day 5 (only Cohort 3) (Each cycle is 28 days)

  6. Pharmacokinetics: Time to Maximum plasma concentration (Tmax)

    Time to Maximum plasma concentration of AUR104

    Time frame: Cycle 1 Day 1 and Day 9 (Cohorts 1, 2, and 3); Cycle 1 Day 5 (only Cohort 3) (Each cycle is 28 days)

  7. Pharmacokinetics: Terminal elimination half-life (t½)

    Terminal elimination half-life of AUR104

    Time frame: Cycle 1 Day 1 and Day 9 (Cohorts 1, 2, and 3); Cycle 1 Day 5 (only Cohort 3) (Each cycle is 28 days)

Other outcomes

  1. Exploratory Endpoint: Changes in the expression of genes

    Pharmacodynamic biomarkers will be assessed by change in expression of genes

    Time frame: Cycle 1 Day 1, Day 2, Day 15, and Cycle 2 Day 1 (Cohort 1 & 2); Cycle 1 Day 1, Day 6, Day 15, and Cycle 2 Day 1 (Cohort 3) (Each cycle is 28 days)

  2. Exploratory Endpoint: Changes in the expression of cytokines

    Pharmacodynamic biomarkers will be assessed by change in expression of cytokines

    Time frame: Cycle 1 Day 1, Day 2, Day 15, and Cycle 2 Day 1 (Cohort 1 & 2); Cycle 1 Day 1, Day 6, Day 15, and Cycle 2 Day 1 (Cohort 3) (Each cycle is 28 days) (Each cycle is 28 days)

  3. Efficacy assessment: Overall response rates (ORR)

    Overall response rates of AUR104 as per Lugano Criteria for NHL/ Hodgkin lymphoma or iwCLL criteria for CLL

    Time frame: Through study completion, an average of 1 year

  4. Efficacy assessment: Duration of response (DOR)

    Duration of response of AUR104 as per Lugano Criteria for NHL/ Hodgkin lymphoma or iwCLL criteria for CLL

    Time frame: Through study completion, an average of 1 year

  5. Efficacy assessment: Progression Free Survival (PFS)

    Progression Free Survival of AUR104 as measured by Lugano Criteria for NHL/ Hodgkin lymphoma or iwCLL criteria for CLL

    Time frame: Through study completion, an average of 1 year

07

Study locations

5 sites
  • Kiran Multi Super Speciality Hospital and Research Centre
    Surat, Gujarat 395004, India
  • Sunshine Global Hospitals
    Surat, Gujarat 395007, India
  • Adwaita Cancer Hospital & ICU
    Surat, Gujarat 395009, India
  • Kolhapur Cancer Centre Pvt. Ltd.
    Kolhāpur, Maharashtra 416234, India
  • MMFHA Joshi Hospital
    Pune, Maharashtra 411004, India
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Feb 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Jan 7, 2025
StartActual
Dec 12, 2024
Primary completionActual
Feb 10, 2026
CompletionActual
Feb 10, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06761586
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Dec 12, 2024
Primary completion
Feb 10, 2026
Completion
Feb 10, 2026
Last update
Apr 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion